Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Short term Debt (2016 - 2024)

Protalix BioTherapeutics has reported Short term Debt over the past 7 years, most recently at $20.4 million for Q2 2024.

  • Quarterly results put Short term Debt at $20.4 million for Q2 2024, changed N/A from a year ago — trailing twelve months through Jun 2024 was $20.4 million (changed N/A YoY), and the annual figure for FY2023 was $20.3 million, changed.
  • Short term Debt for Q2 2024 was $20.4 million at Protalix BioTherapeutics, roughly flat from $20.4 million in the prior quarter.
  • Over the last five years, Short term Debt for PLX hit a ceiling of $56.4 million in Q2 2021 and a floor of $3.2 million in Q3 2021.
  • Median Short term Debt over the past 4 years was $20.4 million (2024), compared with a mean of $31.3 million.